Showing 141-150 of 4704 results for "".
Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oParting Words from Jerry Bagel, MD
https://practicaldermatology.com/columns/clinical-focus-1/parting-words-from-jerry-bagel-md/23085/The psoriasis treatment landscape has changed dramatically during this editor’s tenure.Currents: Cosmetic Advancements In Focus
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/currents-cosmetic-advancements-in-focus/22071/Portfolio Management
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/portfolio-management/19702/Develop and use a portfolio of options to treat facial aesthetic concerns, urges Joel L. Cohen, MD as he talks about injectables, devices, and topicals for use in the cosmetic practice today.What are Dermatologists’ Obstacles to Buy and Bill?
https://practicaldermatology.com/conferences/maui-derm-2024/what-are-dermatologists-obstacles-to-buy-and-bill/20241/Challenges with fee schedules have prompted many dermatologists to consider the buy and bill model. In a conversation between Practical Dermatology’s Chief Medical Editor Neal Bhatia, MD and Mark Kaufmann, MD, associate clinical professor at Mount Sinai, the doctors discuss some of the opportunitiesJournal Club: Efficacy of Systemics After Discontinuation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-efficacy-of-systemics-after-discontinuation/32829/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, is joined by Naiem T. Issa, MD, PhD, to discuss an article Dr. Issa authored reviewing published literature on the efficacy of biologics as monotherapy for atopic dermatitis following discontinuation. Issa NT, Abdin R, et al.Integrity With Industry
https://practicaldermatology.com/programs/practical-dermatology/program-name/39883/Former Chair of the Board of Directors for the National Psoriasis Foundation Colby Evans, MD, provides an update on the SAFE Step Act, and Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Jules Lipoff, Clinical Associate Professor (Adjunct) in the Lewis Katz School of MEight is Great
https://practicaldermatology.com/topics/practice-management/eight-is-great/20899/The inside scoop on the 2016 Cosmetic Surgery Forum.Take 5 With Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
https://practicaldermatology.com/columns/take-5/take-5-with-bobak-azamian-md-phd-chief-executive-officer-and-chairman-of-tarsus-pharmaceuticals/23982/The Importance of the Atopic Dermatitis Pipeline
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37148/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, provides an overview of important research underway involving new therapeutics for the treatment of atop